Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts

Oncology

Volumn 68, Issue 2-3, 2005, Pages 130-137

  Takahashi, Ikuo ^a,b   Emi, Yasunori ^a,b   Kakeji, Yoshihiro ^a   Uchida, Junji ^c   Fukushima, Masakazu ^d   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c Cancer Laboratory   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Docetaxel; Gastric cancer; Nude rat; TS 1; Xenograft

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; TS 1; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TAXOID; TEGAFUR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH CANCER; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; FISCHER 344 RAT; NUDE RAT; STOMACH TUMOR; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; MALE; OXONIC ACID; PYRIDINES; RATS; RATS, INBRED F344; RATS, NUDE; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; TRANSPLANTATION, HETEROLOGOUS;

EID: 23844463887     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086767     Document Type: Article

References (30)

1. The Japanese Gastric Cancer Association (ed): Gastric Cancer Treatment Guidelines, ed 1. Tokyo, Kanahara Shuppan, Tokyo, 2001, pp 12-13 (in Japanese).
2. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T, Sowa M: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997;80:1-7.
3. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K, Toge T: A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 1999;15:921-926.
4. Lokich J, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic oncology program study. J Clin Oncol 1989;7:425-432.
5. Hansen RM: 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. Cancer Invest 1991;9:637-642.
6. Yamao T, Shimada Y, Kondo H, Shirao K, Yokota T, Sugano K, Saito D, Ohkura H, Yoshida S: Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. Jpn J Clin Oncol 1995;25:46-50.
7. Scanlon KJ, Newman EM, Lu Y, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-8925.
8. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997;39:205-211.
9. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulatiors, compared with continuous infusion of 5-fluorouracil. Anti-Cancer Drugs 1998;9:817-823.
10. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S, Shirasaka T: Preclinical antitumor efficacy of S-1: A new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 1998;13:693-698.
11. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
12. Taguchi T, Inuyama M, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi H, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I: Phase I study of S-1. Gan To Kagaku Ryoho 1997;24:2253-2264.
13. Sakata Y, Ohtsu A, Hirokoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur ∼0.4 M gimestat ∼1 M otastat pottassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
14. Koizumi W, Kurihara M, Nakano S, Hasegawa K, and the S-1 gastrointestinal cancer study group: Phase II study for s-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-197.
15. Maehara Y, Sugimachi K, Kurihara M, Taguchi T: Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. Gan To Kagaku Ryoho 1999;26:476-485.
16. Bissery M-C, Nohynek G, Sanderink G-J, Lavelle F: Docetaxel (Taxotere): A review of pre-clinical and clinical experience. Part I: Preclinical experience. Ant-cancer Drugs 1995;6:339-368.
17. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective anti-neoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
18. Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
19. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ohta J, Hirabayashi N: Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese cooperative study group trial (Group A). Gan To Kagaku Ryoho 1998;25:1915-1924.
20. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ohta J, Hirabayashi N, Taguchi T, Furue H: A late phase II study of RP56976 (Docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (Group B). Gan To Kagaku Ryoho 1999;26:487-496.
21. Ando M, Watanabe T, Sasaki Y, Ying DF, Omuro Y, Katsumata N, Narabayashi M, Tokue Y, Fujii H, Igarashi T, Wakita H, Ohtsu T, Itoh K, Adachi I, Taguchi T: A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 1999;77:1937-1943.
22. Lortholary A, Maillart P, Delva R, Boisdron-Celle M, Perad D, Vernillet L, Besenval M, Gamelin E: Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: A phase I, dose-finding study. Eur J Cancer 2000;36:1773-1780.
23. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR): United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia, ed 2. Br J Cancer 1998;77:1-10.
24. Vergniol JC, Bruno R, Montay G, Frydman A: Determination of taxotere in human plasma by a semiautomated high-performance liquid chromatographic method. J Chromatogr 1992;582:273-278.
25. Ikeda M, Masuda H, Yoshisue K, Toko H, Matsushima E, Nagayama S, Kawaguchi Y: Disposition of components of new anti-cancer drug S-1 (8): Species difference, dose proportionality (in Japanese). Yakubutsu Doutai 1997;12:656-667.
26. Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-755.
27. Hirata K, Horikoshi N, Aiba K, Okazaki M, Dennno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-2005.
28. Hill BT, Whelan RDH, Shellard SA, Mcclean S, Hosking LK: Differential tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994;12:169-182.
29. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996;74:704-710.
30. Grem JL, Nguyen D, Monahan BP, Kao V, Geoffroy FJ: Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 1999;58:477-486.